Related references
Note: Only part of the references are listed.Diffuse large B-cell lymphoma: new targets and novel therapies
Bruce D. Cheson et al.
BLOOD CANCER JOURNAL (2021)
IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression
Ahmed Sadik et al.
CELL (2020)
MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma
Chengtao Sun et al.
ONCOTARGETS AND THERAPY (2020)
Investigation of indolamine 2, 3 dioxygenase (IDO-1) gene expression by real-time PCR among patients with lung cancer
Mojtaba Haji Mazdarani et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Yang Liu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma
Yuka Kozuma et al.
EUROPEAN JOURNAL OF CANCER (2018)
1-L-MT, an IDO inhibitor, prevented colitis-associated cancer by inducing CDC20 inhibition-mediated mitotic death of colon cancer cells
Xiuting Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities
Jae Eun Cheong et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer
Wen-Juan Ma et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer
Lijuan Wei et al.
FRONTIERS IN IMMUNOLOGY (2018)
Targeting the IDO1 pathway in cancer: from bench to bedside
Ming Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis
Li Sun et al.
CELL DEATH & DISEASE (2018)
Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
Takefumi Komiya et al.
FRONTIERS IN ONCOLOGY (2018)
TP53 mutation and survival in aggressive B cell lymphoma
Thorsten Zenz et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma
Xue Zhang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Discovery of IDO1 Inhibitors: From Bench to Bedside
George C. Prendergast et al.
CANCER RESEARCH (2017)
An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone
Soo Jeong Nam et al.
LEUKEMIA & LYMPHOMA (2016)
Methyl Sartortuoate Inhibits Colon Cancer Cell Growth by Inducing Apoptosis and G2/M-Phase Arrest
Qiusheng Lan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes With Prognosis
Karen Dybkaer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
FunRich: An open access standalone functional enrichment and interaction network analysis tool
Mohashin Pathan et al.
PROTEOMICS (2015)
Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads
Hongshan Jiang et al.
BMC BIOINFORMATICS (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program
Zijun Y. Xu-Monette et al.
BLOOD (2013)
Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry
Hatem Soliman et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development
Qingjie Ding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Mark Wade et al.
NATURE REVIEWS CANCER (2013)
Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma
Soranobu Ninomiya et al.
LEUKEMIA & LYMPHOMA (2012)
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
Courtney Smith et al.
CANCER DISCOVERY (2012)
Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP
Soranobu Ninomiya et al.
ANNALS OF HEMATOLOGY (2011)
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Bo Li et al.
BMC BIOINFORMATICS (2011)
Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)
E. Drakos et al.
LEUKEMIA (2011)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz et al.
NATURE (2011)
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
Mark D. Robinson et al.
BIOINFORMATICS (2010)
Making sense of ubiquitin ligases that regulate p53
Abhinav K. Jain et al.
CANCER BIOLOGY & THERAPY (2010)
BLIMP1 Is a Tumor Suppressor Gene Frequently Disrupted in Activated B Cell-like Diffuse Large B Cell Lymphoma
Jonathan Mandelbaum et al.
CANCER CELL (2010)
Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP
Takeshi Yoshikawa et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Joshua D. Mezrich et al.
JOURNAL OF IMMUNOLOGY (2010)
The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function
David Warde-Farley et al.
NUCLEIC ACIDS RESEARCH (2010)
Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism
Nam Trung Nguyen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Mara Compagno et al.
NATURE (2009)
p53 polymorphisms: cancer implications
Catherine Whibley et al.
NATURE REVIEWS CANCER (2009)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Share Paper
